EP3020732A4 - Conjugué fc d'immunoglobuline maintenant une force de liaison au fcrn - Google Patents

Conjugué fc d'immunoglobuline maintenant une force de liaison au fcrn

Info

Publication number
EP3020732A4
EP3020732A4 EP14822721.8A EP14822721A EP3020732A4 EP 3020732 A4 EP3020732 A4 EP 3020732A4 EP 14822721 A EP14822721 A EP 14822721A EP 3020732 A4 EP3020732 A4 EP 3020732A4
Authority
EP
European Patent Office
Prior art keywords
immunoglobulin
fcrn binding
binding strength
conjugate
maintaining fcrn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP14822721.8A
Other languages
German (de)
English (en)
Other versions
EP3020732B1 (fr
EP3020732A1 (fr
Inventor
Sang Youn Hwang
Jong Soo Lee
Sung Hee Hong
In Young Choi
Sung Youb Jung
Se Chang Kwon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd, Hanmi Pharmaceutical Industries Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of EP3020732A1 publication Critical patent/EP3020732A1/fr
Publication of EP3020732A4 publication Critical patent/EP3020732A4/fr
Application granted granted Critical
Publication of EP3020732B1 publication Critical patent/EP3020732B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP14822721.8A 2013-07-12 2014-07-14 Conjugué de région fc d'immunoglobuline maintenant l'affinité de liaison du fragment fc de l'immunoglobuline à fcrn Active EP3020732B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130082509 2013-07-12
PCT/KR2014/006328 WO2015005747A1 (fr) 2013-07-12 2014-07-14 Conjugué fc d'immunoglobuline maintenant une force de liaison au fcrn

Publications (3)

Publication Number Publication Date
EP3020732A1 EP3020732A1 (fr) 2016-05-18
EP3020732A4 true EP3020732A4 (fr) 2016-12-28
EP3020732B1 EP3020732B1 (fr) 2020-03-18

Family

ID=52280325

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14822721.8A Active EP3020732B1 (fr) 2013-07-12 2014-07-14 Conjugué de région fc d'immunoglobuline maintenant l'affinité de liaison du fragment fc de l'immunoglobuline à fcrn

Country Status (22)

Country Link
US (2) US20160152684A1 (fr)
EP (1) EP3020732B1 (fr)
JP (2) JP2016525099A (fr)
KR (2) KR101872559B1 (fr)
CN (2) CN105593243A (fr)
AR (1) AR096890A1 (fr)
AU (1) AU2014287879B2 (fr)
CA (1) CA2917838C (fr)
DK (1) DK3020732T3 (fr)
EA (1) EA034297B1 (fr)
ES (1) ES2799326T3 (fr)
HK (1) HK1221957A1 (fr)
HU (1) HU231424B1 (fr)
IL (1) IL243567B (fr)
MX (1) MX2016000344A (fr)
MY (1) MY180374A (fr)
NO (1) NO20160182A1 (fr)
PH (1) PH12016500111A1 (fr)
PT (1) PT3020732T (fr)
TW (1) TWI693236B (fr)
UA (1) UA119644C2 (fr)
WO (1) WO2015005747A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
CA2944138C (fr) * 2014-03-31 2023-06-20 Hanmi Pharm. Co., Ltd. Procede pour ameliorer la solubilite de proteines et de peptides a l'aide de la liaison a un fragment fc d'immunoglobuline
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
CN110312532A (zh) * 2016-12-19 2019-10-08 韩美药品株式会社 脑靶向长效蛋白质缀合物
US20220273808A1 (en) * 2019-07-18 2022-09-01 Hanmi Pharm. Co., Ltd Novel method of preparing protein conjugate
KR102382593B1 (ko) * 2020-01-29 2022-04-05 고려대학교 산학협력단 pH-감응성 Fc 변이체

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047336A1 (fr) * 2003-11-13 2005-05-26 Hanmi Pharmaceutical. Co. Ltd. Complexe proteine utilisant un fragment d'immunoglobuline et son procede de preparation
WO2006107124A1 (fr) * 2005-04-08 2006-10-12 Hanmi Pharmaceutical Co., Ltd. Fragment fc d'immunoglobuline modifie par un polymere non peptidique et composition pharmaceutique contenant ce fragment fc
WO2008136611A1 (fr) * 2007-05-03 2008-11-13 Hanmi Pharmaceutical Co., Ltd. Conjugué peptidique natriurétique utilisant une substance porteuse
WO2010011096A2 (fr) * 2008-07-23 2010-01-28 Hanmi Pharmaceutical Co., Ltd. Complexe de polypeptide comprenant un polymère non-peptidylique ayant trois extrémités fonctionnelles
WO2011122921A2 (fr) * 2010-04-02 2011-10-06 Hanmi Holdings Co., Ltd. Conjugué d'insuline utilisant un fragment d'immunoglobuline
WO2012165915A2 (fr) * 2011-06-02 2012-12-06 Hanmi Science Co., Ltd. Composition pour le traitement du diabète comprenant un conjugué d'insuline à action prolongée et un conjugué de peptide insulinotropique à action prolongée

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (fr) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
ZA200505394B (en) * 2002-12-26 2007-03-28 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
KR100609434B1 (ko) 2004-12-30 2006-08-03 한국항공우주연구원 트랜스버살 필터
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
CN101687933B (zh) * 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
JP5932670B2 (ja) * 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
KR101333958B1 (ko) * 2010-10-20 2013-11-27 주식회사 한독 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
PE20140765A1 (es) 2011-06-10 2014-06-14 Hanmi Science Co Ltd Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
ES2710356T3 (es) * 2011-06-17 2019-04-24 Hanmi Science Co Ltd Conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
MX358491B (es) * 2011-09-05 2018-08-22 Hanmi Science Co Ltd Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047336A1 (fr) * 2003-11-13 2005-05-26 Hanmi Pharmaceutical. Co. Ltd. Complexe proteine utilisant un fragment d'immunoglobuline et son procede de preparation
WO2006107124A1 (fr) * 2005-04-08 2006-10-12 Hanmi Pharmaceutical Co., Ltd. Fragment fc d'immunoglobuline modifie par un polymere non peptidique et composition pharmaceutique contenant ce fragment fc
WO2008136611A1 (fr) * 2007-05-03 2008-11-13 Hanmi Pharmaceutical Co., Ltd. Conjugué peptidique natriurétique utilisant une substance porteuse
WO2010011096A2 (fr) * 2008-07-23 2010-01-28 Hanmi Pharmaceutical Co., Ltd. Complexe de polypeptide comprenant un polymère non-peptidylique ayant trois extrémités fonctionnelles
WO2011122921A2 (fr) * 2010-04-02 2011-10-06 Hanmi Holdings Co., Ltd. Conjugué d'insuline utilisant un fragment d'immunoglobuline
WO2012165915A2 (fr) * 2011-06-02 2012-12-06 Hanmi Science Co., Ltd. Composition pour le traitement du diabète comprenant un conjugué d'insuline à action prolongée et un conjugué de peptide insulinotropique à action prolongée

Also Published As

Publication number Publication date
AU2014287879B2 (en) 2020-01-02
JP2016525099A (ja) 2016-08-22
NO20160182A1 (en) 2016-03-02
EP3020732B1 (fr) 2020-03-18
KR102076718B1 (ko) 2020-02-12
EP3020732A1 (fr) 2016-05-18
DK3020732T3 (da) 2020-06-15
US20160152684A1 (en) 2016-06-02
KR20180071241A (ko) 2018-06-27
US20220380437A1 (en) 2022-12-01
PT3020732T (pt) 2020-06-25
ES2799326T3 (es) 2020-12-16
AR096890A1 (es) 2016-02-03
JP6880278B2 (ja) 2021-06-02
TWI693236B (zh) 2020-05-11
EA034297B1 (ru) 2020-01-27
CN105593243A (zh) 2016-05-18
CA2917838C (fr) 2023-06-20
CA2917838A1 (fr) 2015-01-15
CN116082528A (zh) 2023-05-09
HUP1600206A2 (hu) 2016-05-30
IL243567A0 (en) 2016-03-31
MY180374A (en) 2020-11-28
KR101872559B1 (ko) 2018-06-28
EA201690114A1 (ru) 2016-07-29
NZ716275A (en) 2021-09-24
MX2016000344A (es) 2016-05-05
WO2015005747A1 (fr) 2015-01-15
IL243567B (en) 2020-11-30
JP2020125337A (ja) 2020-08-20
PH12016500111A1 (en) 2016-04-18
TW201546093A (zh) 2015-12-16
HU231424B1 (hu) 2023-08-28
HK1221957A1 (zh) 2017-06-16
KR20150008011A (ko) 2015-01-21
UA119644C2 (uk) 2019-07-25
AU2014287879A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
HK1238648A1 (zh) 與pd-1 結合的抗原結合蛋白
HK1204627A1 (en) Anti-fcrn antibodies fcrn
HK1223951A1 (zh) 具有修飾的 結合性質的 區變體
IL240838A0 (en) Anti-3–lag binding proteins
HK1211297A1 (en) Binding proteins comprising at least two repeat domains against her2 her2
IL240915A0 (en) Dual-specific binding proteins directed against tnfɑ
HK1221957A1 (zh) 維持 結合强度的免疫球蛋白 綴合物
ZA201400062B (en) Tnf-alpha antigen-binding proteins with increased fcrn binding
HK1222182A1 (zh) 三聚體抗原結合分子
HK1208236A1 (en) Antigen binding proteins that bind ccr2 ccr2
ZA201406227B (en) Humanized antibodies that recognize alpha-synuclein
ZA202003612B (en) Engineered immunoglobulins with altered fcrn binding
HK1208474A1 (en) Antigen binding proteins that bind egfr egfr
GB201411301D0 (en) Torsion clamp
JP2016525099A5 (ja) 免疫グロブリンＦｃ断片のＦｃＲｎに対する結合親和力が維持される免疫グロブリンＦｃ結合体
DK3611180T3 (da) Hybrid immunoglobulin indeholdende ikke-peptidyl-binding
EP2969009A4 (fr) Protéines de fusion de fc modifiées
ZA201507808B (en) Binding element
GB201407008D0 (en) Binders
EP3071599A4 (fr) Anticorps hyper-glycosylés à liaison sélective pour le récepteur fc
EP2817324A4 (fr) Protéines de fusion à domaine de liaison de nemo
GB201314294D0 (en) Binding surfaces

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: HWANG, SANG YOUN

Inventor name: KWON, SE CHANG

Inventor name: HONG, SUNG HEE

Inventor name: LEE, JONG SOO

Inventor name: JUNG, SUNG YOUB

Inventor name: CHOI, IN YOUNG

A4 Supplementary search report drawn up and despatched

Effective date: 20161128

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/46 20060101ALI20161122BHEP

Ipc: C07K 19/00 20060101AFI20161122BHEP

Ipc: C07K 14/72 20060101ALI20161122BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1221957

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180511

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20191008

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014062599

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1245813

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200415

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20200611

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3020732

Country of ref document: PT

Date of ref document: 20200625

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20200617

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: NOVAGRAAF INTERNATIONAL SA, CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200618

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200618

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20200401681

Country of ref document: GR

Effective date: 20200916

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200718

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2799326

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20201216

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014062599

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20201221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200714

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1245813

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230602

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20230629

Year of fee payment: 10

Ref country code: FR

Payment date: 20230621

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20230620

Year of fee payment: 10

Ref country code: SE

Payment date: 20230621

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20230621

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230621

Year of fee payment: 10

Ref country code: ES

Payment date: 20230814

Year of fee payment: 10

Ref country code: CH

Payment date: 20230801

Year of fee payment: 10

Ref country code: AT

Payment date: 20230620

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230620

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240620

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240620

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20240621

Year of fee payment: 11

Ref country code: DK

Payment date: 20240625

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240620

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240620

Year of fee payment: 11